Horus Therapeutics launches ProstAsure
This article was originally published in Clinica
Executive Summary
Horus Therapeutics (US) has launched its blood-based prostate cancer test, ProstAsure worldwide. The test has a positive predictive value of 90% for diagnosing prostate cancer and 66% for benign prostate disease. ProstAsure uses neural network computer methodology to discern changes in the activity of relevant biomarkers, including the commonly-used prostate specific antigen (PSA).